Acute Post-Operative Bleeding

1. Clinical Overview

Summary

Post-operative bleeding (POB) is a potentially life-threatening surgical complication characterized by excessive hemorrhage occurring within the post-operative period, ranging from minor self-limiting ooze to catastrophic exsanguination requiring emergency intervention. Major post-operative bleeding is defined as hemoglobin drop > 2g/dL or clinically relevant bleeding requiring intervention (transfusion, endoscopy, or surgery). [1]

The incidence varies by surgical procedure: 3.8-12.1% overall, with higher rates in cardiac surgery (5-7%), vascular procedures (12.1%), and bariatric surgery (3.8-4.7%). [1,2,3] Post-operative bleeding represents the most common early surgical complication after bariatric procedures and a significant contributor to morbidity and mortality across all surgical specialties. [1]

The critical distinction between surgical bleeding (from inadequately controlled vessels, requiring operative intervention) and medical bleeding (from coagulopathy, requiring hemostatic resuscitation) fundamentally determines management strategy and outcomes. Early recognition through clinical vigilance, prompt resuscitation following massive transfusion protocols, and timely decision-making regarding return to theater are the cornerstones of successful management.

Key Facts

• Definition: Major bleeding = hemoglobin drop > 2g/dL or bleeding requiring intervention [1]
• Overall Incidence: 3.8-12.1% depending on surgical procedure [1,2,3]
• Mortality: less than 1% if treated promptly; significantly higher (up to 10-15%) if delayed [4]
• Peak timing: Bimodal - immediate (0-6 hours) or delayed (12-72 hours)
• Critical feature: Hemodynamic instability, tachycardia > 100bpm, hypotension less than 90mmHg systolic
• Key investigation: Serial hemoglobin, coagulation profile, point-of-care viscoelastic testing (TEG/ROTEM) [5,6]
• First-line treatment: ABCDE resuscitation, activate massive transfusion protocol, urgent surgical assessment [7,8]

Clinical Pearls

"Shock plus bleeding equals urgent return to theater" — Hemodynamic instability from post-operative bleeding mandates immediate surgical re-exploration. Every minute of delay increases mortality risk. [4]

"TEG/ROTEM guides what to give" — Point-of-care viscoelastic testing differentiates surgical from coagulopathic bleeding and directs targeted component therapy, reducing empirical transfusion. [5,6]

"Fibrinogen first in massive bleeding" — Fibrinogen levels fall earliest in massive hemorrhage. Target fibrinogen > 1.5-2g/L using cryoprecipitate or fibrinogen concentrate before other factor replacement. [9,10]

"1:1:1 saves lives" — Massive transfusion protocol using 1:1:1 ratio of packed red cells:fresh frozen plasma:platelets reduces mortality in hemorrhagic shock compared to traditional resuscitation. [7,8]

"Don't underestimate concealed blood loss" — Intra-abdominal, retroperitoneal, or intrathoracic bleeding can be massive without visible external signs. Monitor vital signs, drain output, and serial hemoglobin. [2,11]

Why This Matters Clinically

Post-operative bleeding complications are common (affecting 3-12% of surgical patients), potentially catastrophic, yet highly amenable to intervention when recognized early. [1,2,3] The advent of goal-directed hemostatic resuscitation using point-of-care coagulation testing, balanced massive transfusion protocols, and targeted factor replacement has transformed outcomes. [5,6,7,8] However, success depends critically on early recognition, systematic assessment differentiating surgical from medical causes, and decisive intervention. This topic is high-yield for MRCS/FRCS examinations, commonly appearing as viva scenarios requiring candidates to demonstrate systematic approach to the bleeding surgical patient.

---

2. Epidemiology

Incidence & Prevalence

Overall Surgical Procedures:

• Major post-operative bleeding: 3.8-12.1% depending on procedure type [1,2,3]
• Bleeding requiring reoperation: 1-3% of all major surgeries [11]
• Massive transfusion (> 10 units PRBC): 1-2% of elective surgery, up to 15-20% in emergency trauma surgery [7,8]

Procedure-Specific Incidence:

Temporal Trends:

• Incidence stable despite increasing surgical complexity (balanced by improved hemostatic techniques) [13]
• Mortality declining due to massive transfusion protocols and point-of-care testing [7,8]
• Regional variation minimal (standardized surgical practice globally)

Peak Age: All ages; risk increases with age > 70 years due to comorbidities and anticoagulation use [3]

Demographics

Risk Factors

Non-Modifiable Risk Factors:

Modifiable Risk Factors:

The "Lethal Triad" of Trauma (applies to surgical bleeding):

• Hypothermia + Acidosis + Coagulopathy = exponentially increased mortality [15]

Common Causes

Surgical (Technical) Causes (60-70%):

Medical (Coagulopathic) Causes (30-40%):

Mixed Surgical + Medical (10-20%):

• Initially surgical bleeding → depletes clotting factors → coagulopathy develops
• Requires both surgical hemostasis AND hemostatic resuscitation

---

3. Pathophysiology

The Bleeding Cascade

Normal Hemostatic Response to Surgery:

1. Vascular Injury: Surgical incision/dissection → vessel wall damage
2. Primary Hemostasis: Platelet adhesion/activation → platelet plug (within seconds-minutes)
3. Secondary Hemostasis: Coagulation cascade → fibrin clot (within minutes)
4. Surgical Hemostasis: Suture ligation, clips, cautery, hemostatic agents → definitive vessel control
5. Clot Stabilization: Factor XIII cross-links fibrin → stable clot (within hours)

Pathophysiology of Post-Operative Bleeding:

Mechanism 1: Surgical (Anatomical) Bleeding

Inadequate Vessel Control:

• Intraoperatively: Vessel not ligated, clip misplaced, cautery insufficient
• Post-operatively: Ligature slips, clip dislodges, cauterized vessel recanalizes
• Result: Anatomical defect → persistent bleeding from single source
• Diagnosis: Localized bleeding, normal coagulation studies
• Treatment: Surgical re-exploration and vessel control

Unrecognized Vessel Injury:

• During dissection, retraction, or adhesiolysis
• Small vessels (e.g., intercostal, bronchial, lumbar arteries) easily missed
• Bleeding may be slow initially, then accelerate as blood pressure normalizes
• Result: Concealed bleeding into cavity/space
• Diagnosis: Progressive anemia, drain output, normal coagulation
• Treatment: Return to theater for identification and control

Mechanism 2: Coagulopathic (Medical) Bleeding

Dilutional Coagulopathy:

• Mechanism: Massive crystalloid/colloid resuscitation → hemodilution → clotting factor concentration falls below critical threshold (fibrinogen less than 1.5g/L, platelets less than 50×10⁹/L) [7,8,9]
• Timeline: Develops during massive bleeding/resuscitation
• Diagnosis: Diffuse oozing from multiple sites, abnormal coagulation studies, low fibrinogen
• Treatment: Balanced resuscitation (1:1:1 ratio), fibrinogen replacement [7,8,9]

Consumptive Coagulopathy:

• Mechanism: Massive bleeding → consumption of clotting factors faster than hepatic synthesis → factor depletion → impaired clot formation
• Extreme form: Disseminated intravascular coagulation (DIC) with simultaneous thrombosis and bleeding
• Timeline: Develops with massive ongoing bleeding
• Diagnosis: Low fibrinogen, prolonged PT/APTT, low platelets, elevated D-dimer
• Treatment: Control bleeding source, replace factors (MTP), treat underlying cause [7,8]

Fibrinolysis:

• Mechanism: Excessive plasmin activation → fibrin clot breakdown → bleeding
• Causes: Massive trauma, major surgery (especially cardiac/vascular), shock
• Diagnosis: TEG/ROTEM shows hyperfibrinolysis (LY30 > 3% on TEG)
• Treatment: Tranexamic acid (TXA) within 3 hours of bleeding onset [16]

Drug-Induced Coagulopathy:

Hypothermia-Induced Coagulopathy:

• Mechanism: Core temperature less than 36°C → coagulation enzyme activity decreases by 10% per 1°C drop → prolonged clotting times despite normal lab values (measured at 37°C) [15]
• Additional effect: Platelet dysfunction, impaired platelet-endothelial interaction
• Treatment: Active warming (forced-air warming, warmed fluids, increased ambient temperature)

Acidosis-Induced Coagulopathy:

• Mechanism: pH less than 7.2 → impaired coagulation factor function → prolonged clotting [15]
• Causes: Tissue hypoperfusion/shock, lactic acidosis
• Treatment: Restore perfusion, judicious bicarbonate (controversial)

Classification by Timing

Classification by Severity (Modified from Clavien-Dindo)

The "Bloody Vicious Cycle"

Surgical bleeding → Shock/hypoperfusion → Hypothermia + Acidosis → Coagulopathy → More bleeding → Worsening shock → Lethal spiral [15]

Breaking the cycle requires:

1. Stop the bleeding: Surgical hemostasis (damage control surgery if needed)
2. Restore perfusion: Balanced resuscitation (1:1:1 MTP)
3. Correct coagulopathy: Targeted factor replacement (fibrinogen, platelets, factors)
4. Reverse triad: Active warming, restore pH, maintain perfusion
5. Prevent dilution: Avoid excessive crystalloid

---

4. Clinical Presentation

Symptoms: The Patient's Story

Typical Presentation (Moderate Bleeding):

• Weakness/fatigue: Progressive, worsening over hours
• Dizziness/lightheadedness: Especially on sitting up (orthostatic symptoms)
• Shortness of breath: Due to anemia and compensatory tachycardia
• Anxiety: Sense of "not feeling right"
• Recent surgery: Within past 24-72 hours (can be up to weeks for delayed bleeding)

Severe/Life-Threatening Presentation:

• Profound weakness: Unable to mobilize
• Presyncope/syncope: Loss of consciousness
• Severe dyspnea: Respiratory distress
• Confusion/agitation: Cerebral hypoperfusion
• "Sense of impending doom": Classic severe hemorrhage symptom

Key History Points:

Surgical Details:

• Type of surgery: Vascular > cardiac > major abdominal > orthopedic for bleeding risk
• Duration: Prolonged operations (> 4 hours) increase risk
• Intraoperative course: Difficulty with hemostasis, hypotension, large fluid volumes
• Estimated blood loss: If significant intraoperatively, higher post-op risk

Medication History (CRITICAL):

• Anticoagulants: Warfarin, heparin, DOACs (rivaroxaban, apixaban, dabigatran)
• Antiplatelets: Aspirin, clopidogrel, ticagrelor, prasugrel
• When stopped: Ideally 5-7 days pre-op for elective surgery
• Bridging therapy: LMWH bridging increases bleeding risk

Past Medical History:

• Previous bleeding episodes: Suggestive of inherited bleeding disorder
• Liver disease: Reduced clotting factor synthesis
• Chronic kidney disease: Uremic platelet dysfunction
• Diabetes: Increased bleeding complications [1]
• Family history: Hemophilia, von Willebrand disease

Signs: What You See

Vital Signs (Abnormal in Hemorrhage):

General Appearance:

• Pallor: Mucous membranes, conjunctival pallor
• Diaphoresis: Cold sweats
• Restlessness/agitation: Early sign of shock
• Obtundation: Late sign, indicates severe shock

Local Examination Findings:

Visible External Bleeding:

• Wound inspection: Active bleeding from surgical site, soaked dressings
• Frequency: 40-50% of post-op bleeding is visible externally [1]

Concealed Internal Bleeding:

Drain Output (if drains in situ):

• Normal: less than 50mL/h initially, decreasing over 24-48 hours
• Concerning: > 100mL/h persistently, > 200mL in 1 hour, or sudden increase
• Type: Sanguineous (fresh blood) vs serosanguineous (blood-tinged) vs serous (clear)

Signs of Shock (CRITICAL - requires immediate intervention):

Red Flags

[!CAUTION] Red Flags — Immediate Escalation Required:

Hemodynamic Instability:

• Tachycardia > 120 bpm — Indicates significant blood loss (> 30% circulating volume)
• Hypotension SBP less than 90 mmHg — Decompensated shock, requires immediate MTP activation
• Narrow pulse pressure (less than 25 mmHg) — Severe shock
• Altered mental status — Cerebral hypoperfusion, impending cardiovascular collapse

Bleeding Severity:

• Active ongoing bleeding — Cannot be controlled with pressure alone
• Drain output > 200mL/hour — Suggests surgical bleeding requiring re-exploration
• Hemoglobin drop > 2g/dL in 24 hours — Defines major post-operative bleeding [1]
• Hemoglobin less than 7g/dL — Severe anemia, transfusion threshold

Coagulopathy:

• INR > 1.5 without warfarin — Coagulopathy developing
• Platelets less than 50×10⁹/L — Thrombocytopenia contributing to bleeding
• Fibrinogen less than 1.5g/L — Critical fibrinogen depletion, transfuse immediately [9,10]
• Diffuse oozing — Suggests coagulopathy rather than surgical bleeding

Escalation Actions:

1. Activate massive transfusion protocol immediately
2. Emergency surgical consultation — decision for return to theater
3. Transfer to ICU/HDU for invasive monitoring
4. Senior anesthetic support for airway/resuscitation
5. Activate hospital major hemorrhage protocol

---

5. Clinical Examination

Structured Approach: ABCDE Assessment

Post-operative bleeding is a medical emergency. Approach systematically using ABCDE framework:

A - Airway

• Assessment:
  • "Patency: Can patient speak in full sentences?"
  • "Risk: Obtunded patients (shock) at risk of aspiration"
• Action:
  • If GCS less than 8 or unable to protect airway → call anesthetics for intubation
  • "Position: Head-up if conscious and normotensive"

B - Breathing

• Look: Respiratory rate, work of breathing, chest wall movement
  • Tachypnea (> 20/min) = compensatory response to anemia/shock
  • "Hemothorax: Reduced chest wall movement on affected side"
• Listen: Auscultate both lung fields
  • Reduced breath sounds = hemothorax (post-thoracic surgery)
• Measure:
  • "SpO₂: May be normal until severe shock (then less than 90%)"
  • "Respiratory rate: Trend is more important than absolute value"
• Action:
  • High-flow oxygen (15L via non-rebreather mask)
  • If hemothorax suspected → chest X-ray, may need chest drain

C - Circulation (MOST IMPORTANT IN POST-OP BLEEDING)

• Look:
  • "Skin color: Pallor (anemia), mottling (shock)"
  • "Peripheries: Cool/cold extremities (vasoconstriction)"
  • "Capillary refill time: > 2 seconds = poor perfusion"
  • "JVP: Low/flat = hypovolemia"
  • "Visible bleeding: Inspect wound, dressings, drain output"
• Feel:
  • "Pulse: Rate, rhythm, character (weak/thready in shock)"
  • "Peripheries: Temperature (cold = shock)"
• Listen:
  • "Heart sounds: Usually tachycardic, may be quiet if severe hypovolemia"
  • "Blood pressure: Trends more important than single reading"
• Measure:
  • "Heart rate: > 100 bpm = concerning, > 120 bpm = severe bleeding"
  • "Blood pressure: SBP less than 100 mmHg = significant, less than 90 mmHg = activate MTP"
  • "Pulse pressure: Narrow (less than 25 mmHg) = severe shock"
  • "Urine output: less than 0.5mL/kg/h = oliguria from hypoperfusion"
• Action:
  • Large-bore IV access × 2 (minimum 16G, ideally 14G in ACF)
  • "Bloods: FBC, coagulation (PT, APTT, fibrinogen), group & save (or crossmatch 4-6 units), VBG (lactate, base excess)"
  • "IV fluids: Permissive hypotension (target SBP 80-90 mmHg until bleeding controlled) using crystalloid (Hartmann's or 0.9% saline) - avoid excessive volume"
  • Activate MTP if SBP less than 90 mmHg or clinical shock despite resuscitation
  • Urgent surgical review for consideration of return to theater

D - Disability

• Assessment:
  • "AVPU: Alert / Voice / Pain / Unresponsive (or GCS)"
  • Confusion/agitation = cerebral hypoperfusion
  • Obtundation = severe shock, pre-terminal sign
  • "Pupils: Exclude intracranial cause if neurological surgery"
  • "Blood glucose: Exclude hypoglycemia as confounding factor"
• Action:
  • If GCS less than 8 → call anesthetics
  • If confused → indicates severe shock, escalate urgently

E - Exposure

• Look: Full examination of patient, remove all dressings
  • "Wound examination: Remove dressings, inspect surgical site"
    • Active bleeding visible?
    • Hematoma formation? (swelling, ecchymosis, tense)
    • Wound dehiscence?
  • "Abdomen (if abdominal surgery): Distension (hemoperitoneum), peritonism"
  • "Flanks: Grey-Turner sign (retroperitoneal bleeding)"
  • "Drains: Examine all drain outputs"
    • Volume: Measure drain output over past hour/shift
    • Character: Fresh blood vs old blood vs serosanguineous
    • Clots: Presence suggests active bleeding
  • "Per rectum (if pelvic/GI surgery): Fresh blood = anastomotic/luminal bleeding"
• Feel:
  • "Hematoma: Palpate wound edges for expanding collection"
  • "Abdominal distension: Suggests hemoperitoneum"
  • "Tenderness: Peritonism suggests blood irritating peritoneum"
• Action:
  • Document all findings
  • Photograph wound if indicated (medicolegal documentation)
  • Complete full systems examination

Specific Examination Findings

Wound Examination (Critical Skill):

Inspection:

Palpation:

Drain Output Assessment:

Normal Drain Output:

• Post-operative: 50-100mL in first few hours, decreasing
• Character: Serosanguineous (blood-tinged) initially, becoming serous
• Trend: Decreasing volume over time

Abnormal Drain Output Requiring Action:

Special Tests at Bedside:

---

6. Investigations

First-Line (Immediate) - Do Within 15 Minutes

1. Clinical Assessment (MOST IMPORTANT - starts immediately)

• ABCDE assessment: See examination section above
• Vital signs: HR, BP, RR, SpO₂, temperature, urine output
• Trending: Serial vital signs every 15 minutes until stable
• Drain output: Measure volume, inspect character
• Action: Clinical assessment drives all subsequent management

2. Venous Blood Gas (VBG) - CRITICAL POINT-OF-CARE TEST

• Why: Rapid assessment of anemia, lactate, base excess, electrolytes
• Parameters:
  • "Hemoglobin: Crude but immediate estimate (caveat: may be normal immediately post-bleed before hemodilution)"
  • "Lactate: > 2 mmol/L suggests tissue hypoperfusion, > 4 mmol/L = severe shock"
  • "Base excess: -5 or less indicates metabolic acidosis from hypoperfusion"
  • "pH: less than 7.2 impairs coagulation"
  • "K⁺: May be elevated from hemolysis/tissue breakdown"
• Timing: Immediately on IV access, repeat hourly if unstable
• Limitation: Hemoglobin on VBG may lag behind true value in acute bleeding

3. Bedside Ultrasound (FAST Scan)

• Indication: Suspected intra-abdominal bleeding post-abdominal/pelvic surgery
• Views: Morrison's pouch, splenorenal recess, pelvis, pericardium
• Finding: Free fluid (anechoic) = hemoperitoneum
• Sensitivity: 85-95% for significant hemoperitoneum (> 500mL)
• Limitation: Operator-dependent, cannot quantify volume accurately
• Action: Positive FAST + unstable patient = immediate return to theater

Laboratory Tests (URGENT - within 30 minutes)

Full Blood Count (FBC):

Serial Hemoglobin Monitoring:

• Baseline: Pre-operative hemoglobin from pre-assessment clinic
• Post-operative: Immediate post-op (PACU), 6 hours, 12-24 hours
• If bleeding suspected: Every 2-4 hours until stable
• Interpretation: Rate of fall more important than absolute value
  • Drop less than 1g/dL over 6 hours = minimal bleeding
  • Drop 1-2g/dL over 6 hours = moderate bleeding, increase monitoring
  • Drop > 2g/dL over 6 hours = major bleeding, activate MTP [1]

Coagulation Studies (ESSENTIAL):

Key Pearl - Fibrinogen Priority:

Fibrinogen falls FIRST in massive bleeding (before PT/APTT prolong). Target fibrinogen > 1.5-2g/L in actively bleeding patients. [9,10]

Additional Blood Tests:

Point-of-Care Testing: TEG/ROTEM (GOLD STANDARD for Coagulopathy Assessment) [5,6]

Why TEG/ROTEM?

• Standard coagulation tests (PT/APTT) take 30-60 minutes, only assess plasma factors, measured at 37°C (not patient's actual temperature)
• TEG/ROTEM provides results in 10-15 minutes, assesses whole blood (including platelets, fibrinogen, clot strength), performed at patient's temperature
• Guides targeted therapy: Differentiates surgical vs coagulopathic bleeding, directs specific component therapy (FFP vs platelets vs fibrinogen vs TXA) [5,6]
• Reduces transfusion: TEG-guided therapy reduces blood product use by 20-30% compared to empirical transfusion [5,6]

TEG Parameters:

ROTEM Parameters (similar to TEG):

• EXTEM: Extrinsic pathway (equivalent to PT)
• INTEM: Intrinsic pathway (equivalent to APTT)
• FIBTEM: Fibrinogen contribution (platelets blocked)
• APTEM: With aprotinin (detects fibrinolysis)

Critical TEG/ROTEM Differentiations:

Implementation:

• Available in major trauma centers, cardiac surgery centers, some general surgical units
• Requires trained personnel and quality control
• Results in 10-15 minutes (faster than conventional coagulation tests)
• Evidence: Multiple RCTs show TEG/ROTEM-guided therapy reduces transfusion requirements and mortality in bleeding patients [5,6]

Imaging

Generally NOT Required Initially — Post-operative bleeding is a clinical diagnosis requiring urgent intervention. Imaging should not delay resuscitation or return to theater in unstable patients.

Indications for Imaging (in stable or stabilizing patients):

1. Chest X-Ray

• Indication: Post-thoracic surgery with suspected hemothorax
• Finding: Pleural effusion (white-out hemithorax), mediastinal widening
• Action: If large hemothorax (> 1500mL initial output or > 200mL/h ongoing) → consider return to theater

2. Ultrasound (FAST Scan)

• Indication: Suspected hemoperitoneum post-abdominal surgery
• Finding: Free fluid in Morrison's pouch, pelvis
• Limitation: Cannot differentiate blood from other fluids definitively
• Action: Positive FAST + clinical bleeding = return to theater (do not delay for CT)

3. CT Scan with IV Contrast (CT Angiography)

• Indication: Hemodynamically STABLE patient with ongoing bleeding of uncertain source
• Findings:
  • Active extravasation: "Contrast blush" = active arterial bleeding
  • "Hematoma: Hyperdense collection"
  • "Pseudoaneurysm: Focal contrast-filled outpouching"
  • "Retroperitoneal bleeding: Fluid in retroperitoneum (hard to detect clinically)"
• Advantage: Identifies bleeding source, guides intervention (surgical vs interventional radiology)
• Disadvantage: Requires patient transport, takes time (30-60 minutes)
• Contraindication: Hemodynamically unstable patients should go directly to theater, NOT to CT

4. Interventional Radiology (IR) - Angiography ± Embolization

• Indication: Stable patient with CT evidence of arterial bleeding in difficult-to-access location OR bleeding refractory to surgical control
• Examples:
  • Pelvic bleeding post-pelvic surgery (internal iliac branches)
  • Retroperitoneal bleeding (lumbar arteries)
  • Bronchial artery bleeding post-thoracic surgery
  • Bleeding post-liver resection (hepatic artery branches)
• Procedure: Selective catheterization → coil embolization or gelfoam
• Success rate: 85-95% for appropriate lesions
• Limitation: Not suitable for venous bleeding or diffuse oozing (coagulopathy)

Imaging Algorithm:

Suspected Post-Operative Bleeding
         ↓
   Hemodynamically STABLE?
         ↓                    ↓
       YES                   NO
         ↓                    ↓
  Imaging to localize    Direct to Theater
  bleeding source         (No imaging)
         ↓
  CT Angiography
         ↓
  Active extravasation seen?
         ↓                    ↓
       YES                   NO
         ↓                    ↓
  Accessible to IR?      Continue monitoring
   ↓             ↓          vs Surgery
  YES           NO
   ↓             ↓
  Angiography   Surgery
  Embolization

Diagnostic Criteria

Clinical Diagnosis of Major Post-Operative Bleeding:

Definition (any ONE of): [1]

1. Hemoglobin drop > 2g/dL from baseline within 24 hours
2. Hemodynamic instability (HR > 100, SBP less than 100 mmHg) attributed to bleeding
3. Drain output > 200mL/h or > 500mL over 3 hours
4. Visible bleeding requiring intervention
5. Transfusion of ≥2 units PRBC for bleeding

Severity Classification:

Differentiating Surgical vs Coagulopathic Bleeding (CRITICAL):

Key Principle:

Normal coagulation studies + ongoing bleeding = surgical bleeding requiring operative intervention. Abnormal coagulation + diffuse oozing = coagulopathy requiring hemostatic resuscitation. [5,6]

---

7. Management

Management Algorithm

          POST-OPERATIVE BLEEDING SUSPECTED
         (Hemodynamic instability, drain output,
              Hb drop, visible bleeding)
                       ↓
┌──────────────────────────────────────────────────────┐
│         IMMEDIATE ACTIONS (Within 5 minutes)         │
│  1. ABCDE assessment + senior clinician review       │
│  2. Activate major hemorrhage protocol               │
│  3. High-flow O₂, large-bore IV access ×2            │
│  4. Bloods: FBC, coag (incl. fibrinogen), G&S/XM     │
│  5. Activate Massive Transfusion Protocol IF:        │
│     - SBP less than 90 mmHg OR HR > 120 OR shock               │
│  6. Call: Surgeon, Anesthetist, Hematology           │
└──────────────────────────────────────────────────────┘
                       ↓
┌──────────────────────────────────────────────────────┐
│         ASSESS BLEEDING SOURCE & SEVERITY            │
│                                                      │
│  Differentiate: SURGICAL vs COAGULOPATHIC           │
│  • Localized bleeding + normal coag = SURGICAL      │
│  • Diffuse oozing + abnormal coag = COAGULOPATHIC   │
│  • May be MIXED                                      │
└──────────────────────────────────────────────────────┘
                       ↓
      ┌───────────────┴───────────────┐
      ↓                               ↓
HEMODYNAMICALLY STABLE          HEMODYNAMICALLY UNSTABLE
(SBP > 100, HR less than 100)             (SBP less than 90, HR > 120, shock)
      ↓                               ↓
┌─────────────────────┐      ┌──────────────────────────┐
│  MEDICAL MANAGEMENT │      │  ACTIVATE MTP (1:1:1)    │
│  • Optimize coag    │      │  • PRBC : FFP : PLT      │
│  • Monitor closely  │      │  • Fibrinogen if less than 1.5g/L │
│  • Consider imaging │      │  • TXA if hyperfibrinol  │
└─────────────────────┘      │  • Correct Ca²⁺, temp    │
      ↓                      └──────────────────────────┘
Bleeding controlled?                   ↓
  ↓           ↓          ┌──────────────────────────────┐
 YES          NO         │  EMERGENCY SURGERY           │
  ↓           ↓          │  • Immediate return to OR    │
Continue     ↓           │  • Damage control if needed  │
monitoring   ↓           │  • Control bleeding source   │
  ↓          ↓           │  • Don't delay for imaging   │
  ↓    SURGICAL REVIEW   └──────────────────────────────┘
  ↓    Consider return                 ↓
  ↓    to theater       ┌──────────────────────────────┐
  ↓          ↓          │  POST-OP ICU MANAGEMENT      │
  ↓          ↓          │  • Continue MTP if needed    │
  ↓    RETURN TO OR     │  • Invasive monitoring       │
  ↓          ↓          │  • Rewarm, correct acidosis  │
  ↓          ↓          │  • Repeat coag studies       │
  ↓          ↓          │  • May need re-look if DCS   │
  ↓          ↓          └──────────────────────────────┘
  ↓          ↓
  ↓      BLEEDING CONTROLLED
  ↓          ↓
  └──────────┴──────────────────────┐
                                    ↓
              ┌─────────────────────────────────────┐
              │  ONGOING MANAGEMENT                 │
              │  • ICU/HDU monitoring               │
              │  • Serial Hb, coag                  │
              │  • Transfusion threshold Hb 7-8g/dL │
              │  • Thromboprophylaxis when safe     │
              │  • Identify & treat underlying cause│
              └─────────────────────────────────────┘

Acute/Emergency Management - The First Hour (Time-Critical)

Immediate Actions (Do Simultaneously - "Horizontal Resuscitation"):

1. CALL FOR HELP (Within 1 minute)

• Activate major hemorrhage protocol: Brings emergency blood products, senior staff
• Call Surgeon: Consultant or senior registrar capable of re-operation
• Call Anesthetist: Senior anesthetist for airway/resuscitation support
• Call Hematology: If massive transfusion, coagulopathy, or complex transfusion needs
• If appropriate: Activate MTP (see criteria below)

2. AIRWAY & BREATHING (Within 2 minutes)

• High-flow oxygen: 15L via non-rebreather mask (target SpO₂ > 94%)
• Airway assessment: If GCS less than 8 or unable to protect → intubation required
• Consider intubation early if:
  • Ongoing massive bleeding (anticipate deterioration)
  • Transfer to theater imminent
  • Shock requiring massive resuscitation (easier to manage)

3. CIRCULATION (Within 5 minutes) - PRIORITY

IV Access:

• Large-bore IV access × 2: Minimum 16G, ideally 14G in antecubital fossae
• Consider: Central line (femoral) if peripheral access poor (but don't delay resuscitation)
• Rapid infuser: If available, for massive transfusion

Initial Fluid Resuscitation:

• Permissive hypotension until bleeding controlled: Target SBP 80-90 mmHg (avoids "pop the clot" phenomenon) [15]
  • "Exception: Head injury or elderly - target SBP > 100 mmHg"
• Crystalloid: Hartmann's or 0.9% saline, 500mL-1L bolus initially
  • "Limit crystalloid: Maximum 1-2L total (avoid dilutional coagulopathy) [7,8]"
• Switch to blood products as soon as available (see MTP below)

Massive Transfusion Protocol (MTP) Activation Criteria (ANY ONE): [7,8]

1. SBP less than 90 mmHg despite initial fluid resuscitation
2. Heart rate > 120 bpm persistent
3. Clinical shock (hypotension + tachycardia + poor perfusion)
4. Hemoglobin drop > 4g/dL or anticipated need for > 4 units PRBC
5. Ongoing bleeding > 150-200mL/hour (e.g., drain output)
6. "Shock index" (HR/SBP) > 0.9

Massive Transfusion Protocol (MTP) - 1:1:1 Ratio: [7,8]

Evidence-Base:

• Multiple RCTs (PROPPR trial, PROMMT study) show 1:1:1 ratio of PRBC:FFP:Platelets reduces mortality compared to traditional resuscitation in hemorrhagic shock [7,8]
• Mechanism: Prevents dilutional coagulopathy, replaces all blood components proportionally

MTP Pack Composition:

• Pack 1 (initial): 4 units PRBC + 4 units FFP + 1 unit platelets (or 1 pool = 4-6 donor units)
• Subsequent packs: Repeat 1:1:1 ratio until bleeding controlled
• Fibrinogen: Add cryoprecipitate (2 pools = 10 units) or fibrinogen concentrate (3-4g) if fibrinogen less than 1.5g/L [9,10]
• Tranexamic acid (TXA): 1g IV bolus over 10 minutes, then 1g infusion over 8 hours (if less than 3 hours from bleeding onset) [16]

Tranexamic Acid (TXA) in Post-Operative Bleeding: [16]

Evidence:

• CRASH-2 trial (n=20,211): TXA within 3 hours of trauma reduces all-cause mortality (RR 0.91, 95% CI 0.85-0.97) [16]
• Mechanism: Antifibrinolytic - inhibits plasmin, prevents clot breakdown
• Give if: Evidence of hyperfibrinolysis (TEG LY30 > 3%) OR empirically in massive bleeding less than 3 hours onset [16]
• Dose: 1g IV bolus over 10 min, then 1g IV infusion over 8 hours
• Contraindications: Thrombotic risk (VTE, stroke), > 3 hours from bleeding onset (may increase mortality) [16]
• Caution: Do NOT give if bleeding > 3 hours ago (CRASH-2 showed harm) [16]

4. BLOODS (Within 5 minutes - concurrent with IV access)

• FBC: Hemoglobin (but remember may be normal immediately post-bleed)
• Coagulation: PT, APTT, fibrinogen (CRITICAL), platelets
• Group & Save or Crossmatch: 4-6 units PRBC initially (can upgrade to 10+ if MTP)
• VBG: Hemoglobin, lactate (> 2 mmol/L = hypoperfusion), base excess, pH, K⁺, Ca²⁺
• TEG/ROTEM: If available (gold standard for coagulopathy assessment) [5,6]
• Renal function: U&E (AKI from hypoperfusion)

5. MONITORING

• Continuous: ECG (HR), SpO₂, blood pressure (ideally arterial line if MTP)
• Hourly: Urine output (catheterize if not already done - target > 0.5mL/kg/h)
• Drain output: Measure and document hourly
• Serial bloods: Repeat Hb, coag, fibrinogen, VBG every 1-2 hours until stable

6. SPECIFIC INTERVENTIONS (Within 15 minutes)

Stop Anticoagulation/Antiplatelets:

• Withhold all anticoagulants and antiplatelets immediately
• Consider reversal agents (see below)

Correct Coagulopathy:

Warfarin Reversal: [14,17]

• IV Vitamin K: 5-10mg IV (slow infusion, anaphylaxis risk)
  • "Onset: 6-12 hours (too slow for emergency)"
• Prothrombin Complex Concentrate (PCC): 25-50 IU/kg IV (typical dose 2000-3000 IU for 70kg patient)
  • "Onset: Immediate (reverses INR within 10-15 minutes)"
  • "Preferred over FFP: Faster, smaller volume, no ABO compatibility needed [17]"
  • "Evidence: FARES-II trial showed PCC superior to FFP for cardiac surgery bleeding (77.9% vs 60.4% hemostatic effectiveness, pless than 0.001) [17]"
• Fresh Frozen Plasma (FFP): 15-20mL/kg (if PCC unavailable)
  • Slower onset, requires thawing, volume overload risk

DOAC Reversal: [14]

• Dabigatran (Pradaxa): Idarucizumab 5g IV (specific reversal agent)
• Rivaroxaban/Apixaban: Andexanet alfa IV (if available); otherwise PCC 50 IU/kg
• Edoxaban: PCC 50 IU/kg (no specific reversal agent yet)

Heparin Reversal: [14]

• Unfractionated heparin: Protamine sulfate 1mg per 100 units heparin (max 50mg)
• LMWH: Partial reversal with protamine (less effective than for UFH)

Antiplatelet Agents:

• Aspirin/Clopidogrel: No specific reversal; consider DDAVP 0.3 mcg/kg IV (stimulates vWF release, improves platelet function) or platelet transfusion
  • "Note: Platelet transfusion has limited efficacy if drug still circulating (irreversible inhibition of existing platelets, but transfused platelets also affected)"

Fibrinogen Replacement (CRITICAL): [9,10]

Target: Fibrinogen > 1.5-2g/L in actively bleeding patients

Why fibrinogen first?

• Fibrinogen depletes earliest in massive hemorrhage (before other factors)
• Critically low fibrinogen (less than 1g/L) prevents clot formation even if all other factors normal
• Strong evidence for mortality benefit with early fibrinogen replacement [9,10]

Options:

1. Cryoprecipitate: 2 pools (10 units) = raises fibrinogen ~1g/L
   • Advantage: Readily available in UK, also contains factor VIII, vWF, factor XIII
   • Disadvantage: Requires thawing (20-30 min), ABO compatibility needed
2. Fibrinogen Concentrate: 3-4g IV bolus (50mg/kg)
   • Advantage: Immediate availability, no thawing, viral inactivation
   • Disadvantage: Expensive, not universally available

Platelet Transfusion:

• Target: Platelets > 50×10⁹/L in actively bleeding patient, > 100×10⁹/L in neurosurgery/ophthalmic surgery
• Dose: 1 adult therapeutic dose (ATD) = 4-6 donor units = raises platelets ~20-30×10⁹/L

Factor Replacement:

• FFP: 15-20mL/kg (typically 4 units = ~1 liter) if PT/APTT prolonged
  • "Part of MTP 1:1:1 ratio [7,8]"
• PCC: Preferred over FFP for rapid reversal (see above) [17]

7. DECISION: MEDICAL vs SURGICAL MANAGEMENT

CRITICAL DECISION POINT - Return to Theater?

Indications for IMMEDIATE Return to Theater (Surgical Bleeding):

1. Hemodynamic instability despite resuscitation (SBP less than 90, HR > 120 persistent)
2. Massive ongoing bleeding: Drain output > 200mL/h ongoing, or > 1500mL total
3. Normal coagulation + localized bleeding: Suggests surgical source
4. Clinical suspicion of surgical bleeding: Pulsatile bleeding, single-source high output
5. Failed medical management: Bleeding continues despite correcting coagulopathy

Indications for MEDICAL Management (Coagulopathic Bleeding):

1. Hemodynamically stable or stabilizing with resuscitation
2. Diffuse oozing from multiple sites (wound, IV sites, mucosal bleeding)
3. Abnormal coagulation studies: Prolonged PT/APTT, low fibrinogen, low platelets
4. TEG/ROTEM evidence of coagulopathy: Abnormal parameters (see above) [5,6]
5. Known coagulopathy: e.g., on anticoagulation, liver disease

Mixed Picture (Common):

• Initially surgical bleeding → depletes clotting factors → coagulopathy develops
• Requires BOTH surgical control AND hemostatic resuscitation
• Strategy: Control surgical bleeding first (damage control surgery if needed), then optimize coagulation

8. WARMING (Prevent Hypothermia) [15]

• Active warming: Forced-air warming blanket (Bair Hugger), warmed IV fluids, increase ambient temperature
• Target: Core temperature > 36°C
• Rationale: Hypothermia impairs coagulation enzyme function (10% reduction per 1°C drop) [15]

9. CORRECT ACIDOSIS [15]

• Restore perfusion: Adequate resuscitation (improves tissue perfusion → reduces lactate)
• Bicarbonate: Controversial; consider if pH less than 7.1 (50 mmol IV bolus)
• Avoid: Excessive bicarbonate (causes paradoxical intracellular acidosis, shifts oxygen-hemoglobin curve)

10. CORRECT HYPOCALCEMIA

• Mechanism: Massive transfusion → citrate (anticoagulant in blood products) → binds calcium → hypocalcemia → impairs coagulation
• Monitor: Ionized calcium on VBG with each MTP pack
• Treat: If ionized Ca²⁺ less than 1.0 mmol/L → calcium gluconate 10mL 10% IV or calcium chloride 10mL 10% IV (via central line if possible - causes thrombophlebitis)

Surgical Management

Return to Theater - Operative Intervention:

Timing:

• IMMEDIATE: If hemodynamically unstable (don't delay for imaging, full optimization)
• URGENT (within 1-2 hours): If stable but ongoing bleeding despite medical management
• DELAYED: If bleeding controlled, but re-exploration planned (e.g., planned "second look" after damage control surgery)

Procedure:

• Re-exploration: Same incision, evacuate hematoma, identify bleeding source
• Surgical hemostasis: Suture ligation, clips, cautery, hemostatic agents
• If diffuse oozing despite surgical control: Suggests coagulopathy → pack abdomen/wound, temporary closure, return to ICU for resuscitation ("damage control surgery")
• Drains: Usually placed to monitor for re-bleeding

Damage Control Surgery (DCS) - if applicable: [15]

• Concept: Abbreviated surgery to control life-threatening bleeding, avoid "lethal triad"
• Phase 1 (OR): Control hemorrhage, control contamination, pack, temporary closure
• Phase 2 (ICU): Resuscitation, rewarm, correct coagulopathy/acidosis
• Phase 3 (Return to OR): Definitive repair once physiology restored (24-48 hours)
• Evidence: Reduces mortality in severely injured patients; principle applicable to post-op bleeding with lethal triad [15]

Procedure-Specific Considerations:

Bariatric Surgery: [1]

• Gastric Bypass: Luminal bleeding (61.3%) → endoscopy first-line
• Sleeve Gastrectomy: Intra-abdominal bleeding (100%) → surgery first-line
• Strategy: "Endoscopy first for GB, surgery first for SG" [1]

Cardiac Surgery: [12]

• Mediastinal bleeding post-sternotomy
• High threshold for re-exploration (1-3% require reoperation)
• May need mediastinal exploration via sternotomy

Thoracic Surgery: [11]

• Intercostal/bronchial artery bleeding
• Chest tube output: > 200mL/h for > 2-3 hours OR > 1500mL total → consider thoracotomy
• Sources often not identified at re-exploration (20-30%)

Vascular Surgery: [3]

• Anastomotic bleeding, vessel injury
• May require vascular reconstruction

Medical Management (Hemostatic Resuscitation)

Transfusion Thresholds:

Red Blood Cells (PRBC):

• Restrictive strategy (PREFERRED in stable patients): Transfuse if Hb less than 7g/dL [13]
• Liberal strategy (if actively bleeding or cardiovascular disease): Transfuse if Hb less than 8-9g/dL
• Massive bleeding: Use MTP (don't wait for Hb to fall)
• Single-unit transfusion: Reassess after each unit (avoid over-transfusion)

Fresh Frozen Plasma (FFP):

• Indication: PT/APTT > 1.5× normal OR as part of MTP (1:1:1 ratio) [7,8]
• Dose: 15-20mL/kg (typically 4 units)
• Note: PCC preferred over FFP for rapid warfarin reversal [17]

Platelets:

• Threshold: less than 50×10⁹/L in actively bleeding patient (less than 100 in neurosurgery)
• Dose: 1 ATD (adult therapeutic dose) = 4-6 donor units
• MTP: 1 unit platelets per 4 units PRBC [7,8]

Cryoprecipitate/Fibrinogen:

• Threshold: Fibrinogen less than 1.5g/L (or less than 2g/L in massive bleeding) [9,10]
• Dose: 2 pools cryoprecipitate (10 units) or 3-4g fibrinogen concentrate
• Repeat: Check fibrinogen 30 min post-transfusion, repeat if still low

Pharmacological Adjuncts:

Monitoring During Resuscitation:

• Continuous: ECG, SpO₂, blood pressure (arterial line if MTP)
• Hourly: Urine output, drain output, temperature
• Every 1-2 hours: FBC (Hb, platelets), coagulation (PT, APTT, fibrinogen), VBG (lactate, pH, Ca²⁺), TEG/ROTEM
• Target endpoints of resuscitation:
  • HR less than 100 bpm
  • SBP > 100 mmHg (or > 90 if permissive hypotension)
  • Urine output > 0.5mL/kg/h
  • Lactate less than 2 mmol/L (clearing)
  • Base excess >-2
  • Hb > 7-8g/dL
  • Platelets > 50×10⁹/L
  • Fibrinogen > 1.5g/L
  • PT/APTT less than 1.5× normal
  • Temperature > 36°C

Disposition

Admit to ICU/HDU (High Dependency Unit):

Criteria for ICU Admission:

• Hemodynamic instability requiring vasopressors
• Massive transfusion (> 4 units PRBC)
• Ongoing bleeding requiring close monitoring
• Post-operative from emergency re-exploration
• Requiring invasive monitoring (arterial line, central line)
• Multi-organ dysfunction (e.g., AKI, respiratory failure)

Criteria for HDU Admission:

• Hemodynamically stable but requiring frequent monitoring
• Moderate bleeding controlled with transfusion
• Post-operative from re-exploration (stable)

Ward Admission (if stable):

• Minor bleeding, self-limiting
• Hemodynamically stable throughout
• Hemoglobin stable on serial measurements
• Coagulation corrected
• No ongoing transfusion requirements

Discharge Criteria (from Hospital):

• Hemodynamically stable for > 24 hours
• Hemoglobin stable (no drop on serial measurements)
• No active bleeding
• Coagulation normalized
• Tolerating diet
• Adequate analgesia on oral medications
• Safe home environment
• Clear follow-up plan

Follow-Up:

• Surgical outpatient clinic: 1-2 weeks (wound check, ensure recovery)
• Hematology: If bleeding disorder identified or complex transfusion
• Iron supplementation: If anemic post-discharge (oral ferrous sulfate or IV iron)
• Thromboprophylaxis: Resume when bleeding risk low (typically 24-48 hours post-hemostasis)

---

8. Complications

Immediate Complications (Hours - Days)

1. Hemorrhagic Shock [4]

• Incidence: 10-20% of patients with major post-operative bleeding
• Presentation: Hypotension (less than 90 mmHg), tachycardia (> 120), altered mental status, oliguria
• Pathophysiology: Severe blood loss → inadequate tissue perfusion → cellular hypoxia → lactic acidosis → multi-organ dysfunction
• Management: Immediate MTP activation, return to theater, vasopressor support (noradrenaline)
• Mortality: 10-30% if shock develops; lower with rapid intervention [4]

2. Death from Exsanguination [4]

• Incidence: 1-5% of major post-operative bleeding if not treated promptly [4]
• Risk factors: Delayed recognition, delayed return to theater, inadequate resuscitation, coagulopathy
• Prevention: Early recognition, immediate MTP, urgent surgical control
• Key point: Every hour of delay increases mortality risk

3. Transfusion-Related Complications [7,8]

4. Acute Kidney Injury (AKI) [17]

• Incidence: 10-20% of patients with hemorrhagic shock
• Pathophysiology: Renal hypoperfusion → acute tubular necrosis
• Evidence: FARES-II trial: PCC vs FFP reduced AKI (10.3% vs 18.8%, RR 0.55, p=0.02) [17]
• Prevention: Adequate resuscitation, maintain urine output > 0.5mL/kg/h
• Management: Fluid resuscitation, avoid nephrotoxins, may need renal replacement therapy

5. Compartment Syndrome (rare, specific sites)

• Sites: Abdominal (abdominal compartment syndrome from hemoperitoneum), limb (from hematoma)
• Diagnosis: Abdominal: bladder pressure > 20 mmHg + organ dysfunction; Limb: tense swelling, pain, pulses may be present
• Management: Abdominal: decompressive laparotomy; Limb: fasciotomy

Early Complications (Days - Weeks)

1. Re-bleeding [1]

• Incidence: 5-10% of patients
• Causes: Inadequate initial hemostasis, coagulopathy not fully corrected, anticoagulation restarted too early
• Presentation: Recurrent hemodynamic instability, falling hemoglobin, increasing drain output
• Management: Return to theater if significant; optimize coagulation

2. Anemia [13]

• Incidence: 10-30% of patients post-bleeding episode (depending on severity)
• Presentation: Fatigue, dyspnea on exertion, pallor
• Investigations: FBC (low Hb, low MCV if iron deficiency), ferritin (low), iron studies
• Management:
  • "Oral iron: Ferrous sulfate 200mg TDS (or other oral iron preparation)"
  • "IV iron: If intolerant of oral, malabsorption, or need rapid correction (e.g., Ferinject)"
  • "Erythropoietin: Rarely (if chronic kidney disease, avoid in cancer)"
• Follow-up: Repeat FBC at 2-4 weeks to ensure Hb rising

3. Infection [1]

• Incidence: 2-5% (wound infection, intra-abdominal abscess if hematoma becomes infected)
• Risk factors: Hematoma, prolonged surgery, contamination
• Presentation: Fever, wound erythema/discharge, leukocytosis
• Management: Antibiotics, drainage if abscess

4. Thromboembolic Complications (VTE) [14]

• Incidence: 1-3% (paradoxically, bleeding leads to prolonged immobility and delayed thromboprophylaxis)
• Risk factors: Prolonged immobility, delayed mobilization, delayed thromboprophylaxis restart, cancer, obesity
• Prevention: Early mobilization, mechanical prophylaxis (TED stockings, intermittent pneumatic compression), restart pharmacological thromboprophylaxis when bleeding risk low (typically 24-48h post-hemostasis)
• Management: Therapeutic anticoagulation (LMWH or DOAC) if VTE confirmed

5. Critical Illness Myopathy/Neuropathy

• If prolonged ICU stay, sedation, neuromuscular blockers
• Presentation: Weakness, failure to wean from ventilator
• Management: Physiotherapy, rehabilitation

Late Complications (Weeks - Months)

1. Incisional Hernia (if laparotomy)

• Incidence: 5-10% of patients after emergency re-laparotomy (higher than elective surgery)
• Risk factors: Emergency surgery, wound infection, obesity, poor wound healing
• Presentation: Bulge at incision site, discomfort
• Management: Elective hernia repair when patient recovered and optimized

2. Adhesions

• Incidence: Nearly universal after laparotomy
• Complications: Small bowel obstruction (1-3% of patients)
• Prevention: None proven effective
• Management: Conservative (if partial obstruction) vs surgical (if complete obstruction)

3. Psychological Impact (PTSD, anxiety)

• Life-threatening bleeding episode can cause psychological trauma
• Presentation: Anxiety, flashbacks, avoidance, depression
• Management: Psychological support, counseling, may need psychiatric referral

4. Delayed Anemia/Fatigue

• Persistent fatigue for weeks-months post-bleeding
• Causes: Anemia, deconditioning, critical illness
• Management: Iron supplementation, graduated exercise, physiotherapy

---

9. Prognosis & Outcomes

Natural History (Without Effective Treatment)

Untreated Major Post-Operative Bleeding:

• Progression to shock: Almost certain if bleeding > 30% circulating volume (> 1.5L in 70kg patient)
• Mortality: 50-80% if untreated hemorrhagic shock [4]
• Timeline: Death can occur within 1-2 hours of massive bleeding onset (exsanguination)
• Complications: Multi-organ failure, DIC, death

Historical Perspective:

• Before modern transfusion medicine (pre-1940s): mortality from major surgical bleeding > 50%
• Introduction of blood banking (1940s): mortality reduced to 20-30%
• Modern era (MTP, damage control surgery, TEG-guided resuscitation): mortality less than 10% [7,8,15]

Outcomes with Optimal Treatment

Overall Outcomes: [1,4]

Mortality by Severity:

Procedure-Specific Outcomes:

Bariatric Surgery: [1]

• Overall bleeding incidence: 3.8% (GB 5.1%, SG 2.3%)
• Mortality from bleeding: less than 1% (with prompt management)
• Comprehensive complication index (CCI): Higher in bleeding group (47.9 SG vs 31.2 GB)
• Most bleeding managed successfully (75% SG, 48% GB required reoperation)

Vascular Surgery (TCAR): [3]

• Bleeding incidence: 12.1% within 30 days
• 30-day readmission: 42.9% (bleeding) vs 9.8% (no bleeding), pless than 0.001
• Reintervention: 21.4% (bleeding) vs 2.0% (no bleeding), pless than 0.001
• Median length of stay: 1.5 days (bleeding) vs 1 day (no bleeding)

Cardiac Surgery: [12,17]

• Bleeding requiring reoperation: 3-5%
• Mortality from bleeding: 2-5%
• FARES-II trial outcomes (PCC vs FFP): [17]
  • "Hemostatic effectiveness: 77.9% (PCC) vs 60.4% (FFP), pless than 0.001"
  • "Serious adverse events: 36.2% (PCC) vs 47.3% (FFP), RR 0.76, p=0.02"
  • "Acute kidney injury: 10.3% (PCC) vs 18.8% (FFP), RR 0.55, p=0.02"

Time to Recovery:

• Minor bleeding: 3-5 days additional hospital stay
• Moderate bleeding: 5-10 days additional stay
• Severe bleeding requiring reoperation: 10-21 days additional stay, may need ICU (median 2-7 days)
• Full recovery: 4-12 weeks depending on severity and complications

Prognostic Factors

Good Prognosis (Low Mortality, Quick Recovery):

Poor Prognosis (High Mortality, Prolonged Recovery):

Predictive Scoring Systems:

"Shock Index" (Heart Rate / Systolic BP):

• Normal: less than 0.6
• Mild shock: 0.6-0.9
• Severe shock: > 0.9
• Interpretation: > 0.9 = high risk, consider MTP activation

Assessment of Blood Consumption (ABC) Score:

• Predicts need for massive transfusion
• Components: Penetrating mechanism, SBP less than 90, HR > 120, positive FAST
• Score ≥2: 75% sensitivity for massive transfusion

Clavien-Dindo Classification (Surgical Complications):

• Grade I: Any deviation, no intervention
• Grade II: Requires pharmacological treatment (e.g., transfusion)
• Grade IIIa: Requires intervention without general anesthesia (e.g., endoscopy)
• Grade IIIb: Requires intervention under general anesthesia (return to theater)
• Grade IVa: Single organ dysfunction requiring ICU
• Grade IVb: Multi-organ dysfunction
• Grade V: Death
• Post-operative bleeding typically Grade II-V depending on severity

Long-Term Outcomes

Quality of Life:

• Most patients return to baseline quality of life within 3-6 months
• Minority (5-10%) have prolonged fatigue, reduced exercise tolerance
• Psychological impact (anxiety re: surgery) in 10-20%

Return to Normal Activities:

• Light activities: 2-4 weeks
• Full activities/work: 6-12 weeks (depending on occupation and severity)
• Comparable to uncomplicated surgery after initial prolongation

Future Surgery Risk:

• Patients with previous post-operative bleeding at slightly higher risk in future surgeries (1.5-2×)
• Importance of optimizing coagulation, identifying underlying bleeding disorders, careful surgical technique

---

10. Evidence & Guidelines

Key Guidelines

1. European Society of Anaesthesiology (ESA) Guidelines on Management of Severe Perioperative Bleeding (2017)

• Recommendations:
  • Early goal-directed coagulation management using viscoelastic testing (TEG/ROTEM) - Grade 1B
  • Fibrinogen substitution (target > 1.5-2g/L) in bleeding patients - Grade 1B
  • Tranexamic acid in surgical patients with significant bleeding - Grade 1A (based on CRASH-2)
  • Restrictive transfusion strategy (Hb less than 7-8g/dL) unless ongoing bleeding - Grade 1B
• Evidence Level: 1A-1B (high-quality RCTs, systematic reviews)

2. British Committee for Standards in Haematology (BCSH) Guidelines on Blood Transfusion (2016)

• Recommendations:
  • Restrictive red cell transfusion threshold (Hb less than 7g/dL in stable patients, less than 8g/dL in cardiovascular disease)
  • Single-unit transfusion and reassessment
  • Platelet transfusion threshold less than 50×10⁹/L in bleeding patients
  • FFP only if PT/APTT > 1.5× normal OR bleeding with coagulopathy
• Evidence Level: 1A (RCT evidence from TRICC, TRISS trials)

3. National Institute for Health and Care Excellence (NICE) - Blood Transfusion (NG24, 2015)

• Key Points:
  • Do not offer red blood cell transfusion to patients who are hemodynamically stable and have Hb ≥7g/dL
  • Consider transfusion for patients with Hb less than 8g/dL who have cardiovascular disease
  • Use restrictive approach to reduce transfusion-related complications
• Evidence Level: 1A

4. American Society of Anesthesiologists (ASA) Practice Guidelines for Perioperative Blood Management (2015)

• Recommendations:
  • Multimodal blood conservation strategies (patient blood management)
  • Point-of-care coagulation testing to guide transfusion
  • Pharmacological agents (TXA, fibrinogen) to reduce bleeding
  • Restrictive transfusion thresholds
• Evidence Level: 1A-2B (variable quality evidence)

5. Advanced Trauma Life Support (ATLS) Guidelines - American College of Surgeons

• Massive Transfusion Protocol: 1:1:1 ratio of PRBC:FFP:Platelets
• Permissive hypotension: Target SBP 80-90 mmHg until bleeding controlled (trauma context, applicable to surgical bleeding)
• Damage control surgery: Abbreviated surgery, control hemorrhage, temporary closure, resuscitate in ICU
• Evidence Level: 2B-3 (observational studies, expert consensus)

Landmark Trials & Evidence

Massive Transfusion Protocols (1:1:1 Ratio):

1. PROPPR Trial (Pragmatic, Randomized Optimal Platelet and Plasma Ratios) - Holcomb et al., JAMA 2015 [7,8]

• Design: RCT, n=680 trauma patients requiring massive transfusion
• Intervention: 1:1:1 ratio (PRBC:FFP:PLT) vs 1:1:2 ratio
• Results: 1:1:1 ratio → more patients achieved hemostasis (86% vs 78%, p=0.006), trend to reduced 24-hour mortality (12.7% vs 17.0%, p=0.12)
• Conclusion: 1:1:1 ratio preferred for massive transfusion
• Applicability: Trauma data, but principles apply to surgical hemorrhage

2. CRASH-2 Trial (Tranexamic Acid in Trauma) - CRASH-2 Collaborators, Lancet 2010 [16]

• Design: RCT, n=20,211 trauma patients with significant bleeding
• Intervention: Tranexamic acid (TXA) 1g bolus + 1g infusion vs placebo
• Results:
  • All-cause mortality reduced (14.5% vs 16.0%, RR 0.91, 95% CI 0.85-0.97, p=0.0035)
  • Benefit greatest if given less than 3 hours from injury (RR 0.72)
  • Harm if given > 3 hours (RR 1.44, p=0.004) - likely pro-thrombotic effect
• Conclusion: TXA reduces mortality in bleeding trauma patients if given within 3 hours; do NOT give after 3 hours
• Applicability: Trauma data; extrapolated to surgical bleeding with hyperfibrinolysis

Prothrombin Complex Concentrate (PCC) vs Fresh Frozen Plasma (FFP):

3. FARES-II Trial (Four-Factor PCC vs FFP for Coagulopathic Bleeding in Cardiac Surgery) - Karkouti et al., JAMA 2025 [17]

• Design: RCT, n=528 cardiac surgery patients with coagulopathic bleeding post-bypass
• Intervention: PCC (1500-2000 IU) vs FFP (3-4 units)
• Results:
  • "Primary outcome (hemostatic effectiveness): 77.9% (PCC) vs 60.4% (FFP), difference 17.6%, pless than 0.001 for superiority"
  • "Transfusion requirements: PCC group received fewer total blood products (6.6 vs 9.3 units, p=0.002)"
  • "Serious adverse events: 36.2% (PCC) vs 47.3% (FFP), RR 0.76, p=0.02"
  • "Acute kidney injury: 10.3% (PCC) vs 18.8% (FFP), RR 0.55, p=0.02"
• Conclusion: PCC superior to FFP for hemostatic efficacy and safety in cardiac surgery bleeding
• Applicability: High-quality evidence supporting PCC as first-line for rapid reversal of coagulopathy in surgical bleeding

Viscoelastic Testing (TEG/ROTEM):

4. Meta-Analysis of TEG/ROTEM-Guided Transfusion - Wikkelsø et al., Cochrane Review 2016 [5,6]

• Design: Systematic review and meta-analysis, 17 RCTs, n=1,493 patients (mostly cardiac surgery)
• Intervention: TEG/ROTEM-guided transfusion algorithm vs conventional laboratory tests
• Results:
  • Reduced proportion of patients receiving allogeneic blood transfusion (RR 0.86, 95% CI 0.79-0.94)
  • Reduced red cell transfusion (mean difference -0.52 units)
  • Reduced FFP transfusion (mean difference -0.36 units)
  • Trend to reduced mortality (RR 0.65, 95% CI 0.38-1.11, p=0.11)
• Conclusion: TEG/ROTEM-guided therapy reduces blood product transfusion; possible mortality benefit
• Quality: Moderate quality evidence (some studies unblinded, heterogeneity)

Restrictive vs Liberal Transfusion:

5. TRICC Trial (Transfusion Requirements in Critical Care) - Hébert et al., NEJM 1999

• Design: RCT, n=838 ICU patients
• Intervention: Restrictive strategy (transfuse if Hb less than 7g/dL) vs liberal (transfuse if Hb less than 10g/dL)
• Results: 30-day mortality similar (18.7% vs 23.3%, p=0.11); restrictive non-inferior
• Conclusion: Restrictive transfusion strategy safe and reduces blood product use
• Applicability: ICU patients; establishes safety of restrictive approach

6. FOCUS Trial (Transfusion in Hip Fracture) - Carson et al., NEJM 2011

• Design: RCT, n=2,016 hip fracture patients
• Intervention: Restrictive (Hb less than 8g/dL or symptoms) vs liberal (Hb less than 10g/dL)
• Results: 60-day mortality similar (7.6% vs 6.6%, p=0.44); restrictive non-inferior
• Conclusion: Restrictive strategy safe even in elderly surgical patients

Evidence Strength Summary

Strength of Evidence Legend:

• 1A: Systematic review/meta-analysis of RCTs
• 1B: Individual RCT with narrow confidence intervals
• 2A: Systematic review of cohort studies
• 2B: Individual cohort study or low-quality RCT
• 3: Case-control studies, case series
• 4: Expert opinion

---

11. Patient/Layperson Explanation

What is Post-Operative Bleeding?

Post-operative bleeding is bleeding that occurs after surgery. Think of it like this: during surgery, the surgeon cuts through tissues and blood vessels. Normally, these vessels are carefully controlled (tied off, clipped, or sealed) and your body's natural clotting system forms clots to stop bleeding. Post-operative bleeding happens when either a vessel wasn't completely controlled during surgery, or your body's clotting system isn't working properly.

How common is it?

• About 3-12 people out of every 100 who have surgery develop some bleeding afterward
• Most bleeding is minor and stops on its own or with simple treatment
• Serious bleeding requiring urgent treatment happens in about 1-5 people out of 100

In simple terms: You're bleeding after your operation. Sometimes it's from a blood vessel that needs to be sealed by the surgeon. Sometimes it's because your blood isn't clotting properly and needs special medicines or blood products.

Why does it matter?

Post-operative bleeding can be serious or even life-threatening if not treated quickly. The good news is that with modern medicine, we can almost always control it successfully. The key is recognizing it early and getting the right treatment fast.

What can happen if bleeding isn't treated?

• You can lose too much blood, making you feel weak, dizzy, or short of breath
• Your blood pressure can drop (shock), which can affect how your organs work
• In very severe cases, if not treated quickly, it can be life-threatening

But here's the good news: With prompt treatment, more than 95 out of 100 people recover completely. We have excellent treatments including blood transfusions, medicines to help your blood clot, and surgery to stop the bleeding if needed.

How is it treated?

1. Immediate Care (Most Important):

Assessment:

• Your medical team will check your vital signs (heart rate, blood pressure, breathing)
• They'll examine your wound and any drains you have
• They'll do blood tests to check your blood count and how well your blood is clotting

Resuscitation (Supporting Your Body):

• IV drip: You'll get fluids through a drip in your vein to support your blood pressure
• Oxygen: You might be given oxygen through a mask to help your body cope
• Blood transfusion: If you've lost a lot of blood, you'll get donated blood to replace what you've lost
• Why: To keep your blood pressure stable and make sure your organs get enough blood while we stop the bleeding

2. Stop the Bleeding:

There are two main types of bleeding after surgery, and the treatment depends on which type you have:

Type 1: Surgical Bleeding (from a blood vessel)

• What it means: A blood vessel that was controlled during surgery has started bleeding again (maybe a tie came loose, or a clip moved)
• How we know: Usually you have bleeding from one specific area, and your blood tests show your clotting is normal
• Treatment: You'll need to go back to the operating room so the surgeon can find the bleeding vessel and stop it (by tying it off, clipping it, or sealing it)
• Success rate: Very high - once the surgeon finds and controls the vessel, bleeding stops

Type 2: Medical Bleeding (from clotting problems)

• What it means: Your blood isn't clotting properly, so you're oozing from multiple places (wound, IV sites, etc.)
• How we know: You have oozing from many sites, and blood tests show clotting problems
• Treatment: Special blood products and medicines to help your blood clot:
  • "Fresh frozen plasma (FFP): Contains clotting proteins"
  • "Cryoprecipitate or fibrinogen: A specific clotting protein that's often low in bleeding"
  • "Platelets: Small cells that help form clots"
  • "Medicines: Like tranexamic acid (helps stop clots from breaking down) or vitamin K (if you were on blood thinners)"
• Success rate: Very good - once we correct the clotting problem, bleeding usually stops

Often it's a combination: Initially surgical bleeding → this uses up clotting proteins → then coagulation bleeding develops. In this case, you need BOTH: surgery to stop the vessel AND blood products to fix clotting.

3. Monitoring and Recovery:

After bleeding is controlled:

• You'll be monitored closely (possibly in intensive care or high-dependency unit)
• Regular blood tests to make sure your blood count and clotting stay stable
• Pain relief medication
• Gradual return to eating and mobilizing as you recover

How long does recovery take?

• If bleeding was minor and stopped quickly: Usually a few extra days in hospital
• If bleeding was more serious and you needed surgery or lots of blood: 1-2 weeks in hospital, then 4-12 weeks to feel fully recovered at home

What to expect

In Hospital:

• Close monitoring: Your nurses will check your vital signs frequently (heart rate, blood pressure, etc.)
• Blood tests: Regular blood tests to check your blood count
• Drains: If you have drains, they'll be monitored to see how much fluid is draining
• Transfusions: You might need blood transfusions (donated blood given through your IV)
• Possible return to theater: If bleeding is from a blood vessel, you might need another operation to stop it
• Pain: You'll have pain relief medication to keep you comfortable

After Hospital:

• Fatigue: You'll feel tired for several weeks (you've lost blood and been through a stressful experience)
• Iron tablets: You might be given iron tablets to help your body rebuild its blood
• Gradual recovery: It usually takes 4-12 weeks to feel back to normal
• Follow-up: You'll have appointments to check your recovery and make sure everything is healing

Long-term:

• Most people make a full recovery with no long-term problems
• Very occasionally, if bleeding was severe, you might have some longer-term effects (like scarring or need for further surgery for complications), but this is rare

When to seek help

If you're in hospital after surgery, tell your nurse immediately if:

• You feel very weak, dizzy, or faint
• You're feeling short of breath
• You notice bleeding from your wound or drains
• You feel your heart racing
• You feel very unwell or "something isn't right"

If you've been discharged home, call 999 (or your emergency number) immediately if:

• You have heavy bleeding from your wound
• You feel very weak, dizzy, or faint
• You have a fast heart rate and feel unwell
• You're feeling very short of breath
• You have chest pain

See your doctor (non-emergency) if:

• You have minor bleeding from your wound that concerns you
• You're feeling more tired than you'd expect
• You have any other symptoms that worry you

Remember

Post-operative bleeding is serious, but it's also very treatable when caught early. Modern medicine has excellent tools to stop bleeding and support your body while you recover. The medical team looking after you has dealt with this many times before and knows exactly what to do.

Most important things to know:

1. We can almost always stop the bleeding - with blood products, medicines, or surgery
2. Early treatment is crucial - that's why we monitor you so closely after surgery
3. Most people make a full recovery - more than 95 out of 100 people recover completely
4. You're not alone - this happens to several people out of every 100 who have surgery, and we know how to manage it

If you're worried about anything, always ask your medical team. There are no silly questions, and we want you to understand what's happening and feel reassured.

---

12. References

Primary Guidelines & Systematic Reviews

1. Kollmann L, Gruber M, Lock JF, et al. Clinical Management of Major Postoperative Bleeding After Bariatric Surgery. Obes Surg. 2024;34(3):751-759. doi:10.1007/s11695-023-07040-0

2. Helmy RF, Elbanna MR, El-Zemeity AO, et al. Management of Early Postoperative Bleeding After OAGB: A Single-center Experience. Surg Laparosc Endosc Percutan Tech. 2023;33(6):617-621. doi:10.1097/SLE.0000000000001232

3. Cui CL, Pride LB, Loanzon RS, et al. Postoperative Bleeding Complications are Common among Patients Undergoing Transcarotid Artery Revascularization. Ann Vasc Surg. 2025;110(Pt A):144-152. doi:10.1016/j.avsg.2024.07.109

4. Desai N, Schofield N, Richards T. Perioperative Patient Blood Management to Improve Outcomes. Anesth Analg. 2018;127(5):1211-1220. doi:10.1213/ANE.0000000000002549

Point-of-Care Testing (TEG/ROTEM)

5. Wikkelsø A, Wetterslev J, Møller AM, et al. Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding. Cochrane Database Syst Rev. 2016;2016(8):CD007871. doi:10.1002/14651858.CD007871.pub3

6. Gonzalez E, Moore EE, Moore HB. Goal-directed Hemostatic Resuscitation of Trauma-induced Coagulopathy: A Pragmatic Randomized Clinical Trial Comparing a Viscoelastic Assay to Conventional Coagulation Assays. Ann Surg. 2016;263(6):1051-1059. doi:10.1097/SLA.0000000000001608

Massive Transfusion Protocols

7. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313(5):471-482. doi:10.1001/jama.2015.12

8. Holcomb JB, del Junco DJ, Fox EE, et al. The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks. JAMA Surg. 2013;148(2):127-136. doi:10.1001/2013.jamasurg.387

Fibrinogen Replacement

9. Rourke C, Curry N, Khan S, et al. Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. J Thromb Haemost. 2012;10(7):1342-1351. doi:10.1111/j.1538-7836.2012.04752.x

10. Innerhofer P, Fries D, Mittermayr M, et al. Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial. Lancet Haematol. 2017;4(6):e258-e271. doi:10.1016/S2352-3026(17)30077-7

Surgical Management

11. Maniwa Y. Postoperative Intrathoracic Hemorrhage; Perioperative Prevention and Management. Kyobu Geka. 2017;70(8):688-691. [Article in Japanese]

12. Vivacqua A, Koch CG, Yousuf AM, et al. Morbidity of bleeding after cardiac surgery: is it blood transfusion, reoperation for bleeding, or both? Ann Thorac Surg. 2011;91(6):1780-1790. doi:10.1016/j.athoracsur.2011.03.105

Patient Blood Management

13. Munoz M, Acheson AG, Auerbach M, et al. International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia. 2017;72(2):233-247. doi:10.1111/anae.13773

Anticoagulation Reversal

14. Narouze S, Benzon HT, Provenzano D, et al. Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition): Guidelines From the American Society of Regional Anesthesia and Pain Medicine. Reg Anesth Pain Med. 2018;43(3):225-262. doi:10.1097/AAP.0000000000000700

Damage Control & Lethal Triad

15. Duchesne JC, McSwain NE Jr, Cotton BA, et al. Damage control resuscitation: the new face of damage control. J Trauma. 2010;69(4):976-990. doi:10.1097/TA.0b013e3181f2abc9

Tranexamic Acid

16. CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23-32. doi:10.1016/S0140-6736(10)60835-5

Prothrombin Complex Concentrate

17. Karkouti K, Callum JL, Bartoszko J, et al. Prothrombin Complex Concentrate vs Frozen Plasma for Coagulopathic Bleeding in Cardiac Surgery: The FARES-II Multicenter Randomized Clinical Trial. JAMA. 2025;333(20):1781-1792. doi:10.1001/jama.2025.3501

Additional Key References

18. European Society of Anaesthesiology. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2017;34(6):332-395. doi:10.1097/EJA.0000000000000630

19. National Institute for Health and Care Excellence. Blood transfusion. NICE guideline [NG24]. 2015. Available at: https://www.nice.org.uk/guidance/ng24

20. British Committee for Standards in Haematology. Guidelines on the management of massive blood loss. Br J Haematol. 2006;135(5):634-641. doi:10.1111/j.1365-2141.2006.06355.x

---

Last Reviewed: 2026-01-10 | MedVellum Editorial Team

Topic Number: 922/1071

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and local protocols. Always consult appropriate senior clinicians and follow institutional guidelines. This information is not a substitute for professional medical judgment. All treatment decisions must be individualized to the patient and local resources.